Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Neuroprotective agents].

A Dávalos1

  • 1Sección de Neurología, Hospital Universitari de Girona Doctor Josep Trueta.

Neurologia (Barcelona, Spain)
|December 29, 1999
PubMed
Summary
This summary is machine-generated.

Despite promising preclinical results, most neuroprotective drugs failed in clinical trials for acute ischemic stroke. Promising candidates like ebselen and citicoline show potential, offering hope for future stroke treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ischaemic stroke as a complication of cardiac catheterisation. Clinical and radiological characteristics, progression, and therapeutic implications.

Neurologia·2022
Same author

Safety and outcomes of routine endovascular thrombectomy in large artery occlusion recorded in the SITS Register: An observational study.

Journal of internal medicine·2021
Same author

Effect of atrial fibrillation on endovascular thrombectomy for acute ischemic stroke. A meta-analysis of individual patient data from six randomised trials: Results from the HERMES collaboration.

European stroke journal·2020
Same author

[Clinical characteristics of patients with stroke code activation not identified by the emergency medical service].

Revista de neurologia·2020
Same author

Ischaemic stroke as a complication of cardiac catheterisation. Clinical and radiological characteristics, progression, and therapeutic implications.

Neurologia·2019
Same author

[Novel oral anticoagulants in non-valvular atrial fibrillation: How to improve its management in Spain].

Semergen·2018
Same journal

[Amyotrophic neuralgia secondary to Vaxzevria (AstraZeneca) COVID-19 vaccine].

Neurologia (Barcelona, Spain)·2024
Same journal

[SARS-CoV-2 infection: Possible underdiagnosis of cerebral venous sinus thrombosis].

Neurologia (Barcelona, Spain)·2024
Same journal

[Bell's palsy following COVID-19 vaccination: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Parsonage-Turner syndrome post-infection by SARS-CoV-2: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Acute transverse myelitis following SARS-CoV-2 infection].

Neurologia (Barcelona, Spain)·2024
Same journal

[Neurological complications in critical patients with COVID-19].

Neurologia (Barcelona, Spain)·2024
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Ischemic Stroke Research

Context:

  • Numerous neuroprotective compounds targeting the ischemic cascade have been developed over the last decade.
  • Experimental stroke models show efficacy in reducing infarct volume, but this has not translated to clinical success in reducing mortality or morbidity.
  • Discrepancies between laboratory findings and clinical outcomes necessitate a review of factors influencing drug efficacy.

Purpose:

  • To analyze the reasons behind the failure of neuroprotective drugs in clinical trials for acute ischemic stroke.
  • To review neuroprotective agents that have been investigated in human patients with acute ischemic stroke.
  • To identify potential future therapeutic strategies for stroke neuroprotection.

Summary:

  • Most neuroprotective drugs, despite reducing infarct volume in animal models, have failed in clinical trials for acute ischemic stroke.

Related Experiment Videos

  • Many drug candidates were discontinued due to safety concerns.
  • Ebselen (antioxidant) and citicoline (cell membrane stabilizer) show preliminary beneficial effects, while trafermin and glycine antagonists are in advanced clinical trials.

    • Impact:

    • Understanding the gap between preclinical and clinical results is crucial for developing effective stroke therapies.
    • Ebselen and citicoline represent potential advancements in managing acute ischemic stroke.
    • Ongoing clinical investigations of drugs like trafermin and glycine antagonists may significantly alter the future landscape of neuroprotection in stroke treatment.